- Home
- HUMA vs YMAB Comparison
HUMA vs YMAB Comparison
Compare HUMA & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUMA
- YMAB
- Stock Information
- Founded
- HUMA 2004
- YMAB 2015
- Country
- HUMA United States
- YMAB United States
- Employees
- HUMA N/A
- YMAB N/A
- Industry
- HUMA Biotechnology: Pharmaceutical Preparations
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- HUMA Health Care
- YMAB Health Care
- Exchange
- HUMA Nasdaq
- YMAB Nasdaq
- Market Cap
- HUMA 577.7M
- YMAB 482.4M
- IPO Year
- HUMA N/A
- YMAB 2018
- Fundamental
- Price
- HUMA $4.64
- YMAB $8.28
- Analyst Decision
- HUMA Strong Buy
- YMAB Strong Buy
- Analyst Count
- HUMA 7
- YMAB 10
- Target Price
- HUMA $13.14
- YMAB $21.00
- AVG Volume (30 Days)
- HUMA 6.3M
- YMAB 303.4K
- Earning Date
- HUMA 11-08-2024
- YMAB 11-08-2024
- Dividend Yield
- HUMA N/A
- YMAB N/A
- EPS Growth
- HUMA N/A
- YMAB N/A
- EPS
- HUMA N/A
- YMAB N/A
- Revenue
- HUMA N/A
- YMAB $84,553,000.00
- Revenue This Year
- HUMA N/A
- YMAB $6.46
- Revenue Next Year
- HUMA $6,438.24
- YMAB $20.68
- P/E Ratio
- HUMA N/A
- YMAB N/A
- Revenue Growth
- HUMA N/A
- YMAB N/A
- 52 Week Low
- HUMA $2.48
- YMAB $6.29
- 52 Week High
- HUMA $9.97
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- HUMA 53.53
- YMAB 25.63
- Support Level
- HUMA $3.37
- YMAB $9.31
- Resistance Level
- HUMA $4.42
- YMAB $11.10
- Average True Range (ATR)
- HUMA 0.50
- YMAB 0.72
- MACD
- HUMA 0.01
- YMAB -0.09
- Stochastic Oscillator
- HUMA 37.35
- YMAB 7.35
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.